Nail Psoriasis Blinded STUDY SYNOPSIS
|
|
- Sydney Simon
- 6 years ago
- Views:
Transcription
1 Nail Psoriasis Blinded STUDY SYNOPSIS Study Title Development Phase Phase 3 Study Medication Primary Objective Secondary Objectives A randomized, double-blind, vehicle-controlled, parallel-group trial to assess the efficacy, safety and tolerability of [STUDY DRUG] for topical treatment of nail psoriasis. Group A: [STUDY DRUG] once a day Group B: Vehicle once a day To assess the efficacy of topical [STUDY DRUG] in the treatment of mild to moderate psoriatic fingernail/s (defined as fingernail/s with matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score 1 and 3 at baseline). To assess if the topical treatment with [STUDY DRUG] is able to improve the quality of life and discomfort in patients with psoriatic fingernail. To assess the safety and tolerability of topical [STUDY DRUG] in the treatment of psoriatic fingernail. Primary Endpoint Proportion of patients with clear target nail (NAPSI=0) at Week 24 Secondary Endpoints Exploratory Endpoints Other Endpoints Proportion of affected nails at baseline with NAPSI = 0 at Week 24 Proportion of patients with clear target nail bed (bed NAPSI = 0) at Week 24 Proportion of patients with clear target nail matrix (matrix NAPSI = 0) at Week 24 Proportion of patients with target nail reaching NAPSI-75% at Week 24 Proportion of affected nails at baseline reaching NAPSI-75% at Week 24 Change from baseline in Total NAPSI at Week 24 Time to reach NAPSI = 0 in the target nail Nail PGA response rates Change from baseline in in nail psoriasis VAS discomfort at Week 24 Patient acceptance of study therapy at Week 24 Health Outcome Assessments: EQ-5D, DLQI, SF36 and NPQ10 Safety and tolerability outcomes: Adverse events, skin irritation severity score; laboratory tests and vital signs. Others: Exposure to study medication, treatment compliance, prior medication and concomitant medication, quality of life and reasons for withdrawal.
2 Study Design Study Population and Procedures This is a multicenter, randomized, double-blind, vehiclecontrolled, parallel- group, phase 3, pivotal study. Patients with mild to moderate psoriatic fingernail/s, defined as fingernail/s with matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score 1 and 3 at baseline, will be recruited. The sum of the scores for each nail should range between 1 and 6. The study consists of two arms comparing [STUDY DRUG] and vehicle. Patients meeting the main inclusion criteria will enter the study and will be randomly allocated to one of the two treatment groups: Group A: [STUDY DRUG] Group B: vehicle. Patients will apply the assigned treatment to the affected psoriatic fingernails once daily for 24 weeks. The nails will not be washed for at least six hours after application; therefore, it will be recommended to preferably apply the product before bedtime. Patients should avoid face contact. To remove the product, it is sufficient to wash the nails. No solvent is needed. At the Screening Visit (V0), at visits V2, V3, V4, V5, at the end of treatment period V6 and at the follow-up visit (V7): The Investigator will assess the severity of the pathology and record NAPSI and Nail PGA scores for all affected fingernails. The patient will assess their discomfort on a VAS. The patient will fill-in the quality of life questionnaire. The Investigator will take 4 digital photos under standardized conditions: one photo of the left hand thumb, left hand four fingers, right hand thumb, and the right hand four fingers. At the Screening Visit, the photos will be taken before scraping for KOH direct examination. At the end of the treatment (V6 or early discontinuation), patients will evaluate the acceptability of the study therapy. Safety and tolerability will be monitored throughout the study: safety laboratory investigations (including calcium levels inplasma and urine) will be evaluated at the Screening Visit, at Week 16 and at the End of Treatment or, if applicable, at the early discontinuation visit. Vital signs will be reported at the Screening Visit and at the End of Treatment (V6) or, if applicable, at an early discontinuation visit. The safety analysis will be performed by the central Lab.Adverse Events will be reported at each study visit including any possible
3 Criteria for evaluation skin irritation. Safety Measurements Adverse Events All adverse events (AEs) experienced by a patient during the entire study period must be recorded in the patient s Case Report Form. An AE is any untoward occurrence for a patient or subject undergoing a clinical investigation while receiving a medicinal product, irrespective of whether or not the untoward occurrence is considered related to the product. All markedly abnormal laboratory test results must always be reported as AEs. Any clinically significant changes in vital signs should also be recorded as an AE. Safety Laboratory Test Safety laboratory tests will be performed at the screening, at week 16 and at the end of the treatment period (Week 24) or at the discontinuation visit. These tests will include: haematology, clinical chemistry and urinalysis. The following variables will be measured: Haematology: haemoglobin concentration, haematocrit, red blood cell count and white blood cell count with differential and platelet count. Clinical Chemistry: transaminases (AST, ALT), total serum bilirubin (direct and indirect), γgt, alkaline phosphatase, serum creatinine, blood urea nitrogen, uric acid, glucose, cholesterol, triglycerides, potassium, magnesium, calcium, phosphorus, chloride, protein and albumin. Urinalysis: protein content, glucose content, haemoglobin content, WBC content in sediment, RBC content in sediment, crystals content in sediment, casts content in sediment, calciuria, phosphaturia. Physical examination A complete physical examination will be performed at the screening visit (V0), at the end of the treatment period (Week 24) and at the end of follow-up (week 28) or at the discontinuation visit. Vital signs Sitting systolic and diastolic blood pressure from the same arm, pulse (after 3 minutes sitting) and temperature will be measured at the screening visit, at the end of the treatment period (Week 24) and at the end of follow-up (week 28) or at the discontinuation
4 visit. Pregnancy Test A urine pregnancy test will be done locally, at each study site and at each study visit until the end of the treatment, to each woman of childbearing potential and to each menopausal woman (if menopause is less than one year) by means of a reagent stick. Severity Score of Skin Irritation Local tolerability at the application site will be assessed to rate the severity of any periungual irritation during the treatment period using the following Skin Irritation Severity Score: Score Dermal response 0 No evidence of irritation 1 Minimal erythema, barely perceptible 2 Definite erythema, readily visible; minimal edema or minimal papular response 3 Erythema and papules 4 Definite edema 5 Erythema, edema and papules 6 Vesicular eruption 7 Strong reaction spreading beyond test site Score A B C D F G Other effects Slight glazed appearance Marked glazing Glazing with peeling and cracking Glazing with fissures Film of dried serous exudate covering all or part of the patch site Small petechial erosions or scabs Efficacy Measurements Nail Psoriasis Severity Index (NAPSI) To assign a score to each nail for nail bed and nail matrix psoriasis, the Nail Psoriasis Severity Index (NAPSI) will be used. The nail plate is divided into four quadrants by imaginary longitudinal and horizontal lines. Nail matrix psoriasis is assessed by the presence of any feature of nail matrix psoriasis, including nail pitting, leukonychia, red spots in the lunula, and crumbling in each quadrant of the nail. Nail bed psoriasis is assessed by the presence of any features of nail bed psoriasis, including onycholysis, oil drop (salmon patch) dyschromia, splinter haemorrhages, and nail
5 bed hyperkeratosis in each quadrant of the nail. The score is 0 if the findings are not present, 1 if they are present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail. Thus each nail has a matrix score (0-4) and a nail bed score (0-4), and the total nail score is the sum of those two (0-8). The sum of the scores from all involved fingernails is 0-80 (Total NAPSI score for that patient at that time) and represents the total score 11. Nail Physician Global Assessment (PGA) Each fingernail bed and matrix is scored on a 5-point scale, from clear (0) to severe-markedly involved (4) which correlates with the percentage of fingernail area affected (from no visible sign to signs involving greater than 51% of the nail). The highest of either score (bed or matrix) corresponds to the Nail PGA score for that nail.. VAS of discomfort A Visual Analogue Scale (VAS) is an instrument that is used to measure the amount of discomfort that the patient feels in the nail and ranges from no discomfort to worst possible discomfort. The VAS is a horizontal line, 100 mm in length, with descriptive words at each end. The patients mark on the line the point that they feel represents their perception of their current state of discomfort. The VAS score is determined by measuring in millimeters from the left side of the line to the point that has been marked by the patient. Quality of life and Health Outcomes At the screening visit (Visit -1, Baseline), and every postrandomization visit, patients will complete the Dermatology Life Quality Index (DLQI) 13 the EuroQoL-5D (EQ-5D) 14, SF and NPQ10 16 questionnaires. The DLQI is designed to evaluate quality-of-life in dermatological patients affected by chronic diseases. The EQ-5D is a measure of health outcome applicable to a wide range of health conditions. The Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) is an indicator of overall health status. The Nail Psoriasis Quality of Life Index (NPQ10) was developed to measure life quality impairment due to nail psoriasis and its modification in the course of treatment. Patient Acceptance of Study Therapy At the End of Treatment (V6 or at an early discontinuation), patients will evaluate the acceptability of the study therapy on a 4- point scale from 1 (Poor) to 4 (Very Good).
6 Inclusion criteria Written informed consent before starting any study-related procedure. Patients aged 18 and 80 years old. Men or women. Outpatients. Patients with mild to moderate psoriastic fingernail(s) defined as fingernail/s with matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score 1 and 3 at baseline. The sum of the scores for each nail should range between 1 and 6. In case of skin involvement, patients with established clinical diagnosis of mild-to-moderate psoriasis (BSA involvement 8% or PASI 10). Exclusion criteria Use of any systemic treatment for psoriasis and/or nail psoriasis during the last six months before the screening visit. Use of any topical treatment for nail psoriasis on fingernail during the last six months before the screening visit. Use of photochemotherapy (phototherapy is allowed) or other forms of radiotherapy during the last four weeks before the screening visit. Positive mycology findings (KOH evaluation or culture) obtained in the three months before the screening visit or positive KOH evaluated at the screening visit. Patients using nail polish or other nail cosmetic products during last 72 hours prior to study drug application. Systemic use of the following therapies for any reason during last three months before the screening visit: immunosuppressives, chemotherapy and corticosteroids (topical use for plaque psoriasis is allowed).consumption of oral Vitamin D or its analogues for any reason during the last three months before the screening visit (calcipotriene topical use for plaque psoriasis is allowed). Patients with a clinically significant history of cardiovascular, renal, neurologic, liver, immunologic or endocrine dysfunction. A clinically significant disease is defined as one that in the opinion of the investigator may either put the patient at risk because of participation in the study or is a disease that may influence the results of the study or the patient s ability to participate in the study. Patients with a recent history (< 1 year) of myocardial infarction and/or (< 3 years) of heart failure or patients with any cardiac arrhythmia requiring drug therapy. History of hypercalcaemia or hypercalciuria. History of previous or current malignancy; in particular lymphoma, melanoma and/or basal cell carcinoma.
7 Randomization Product application and removal Study visits History of allergic reactions to Calcipotriene or [STUDY DRUG] excipients. Patients unable to understand the procedures and purposes of the study. Patients unable or unwilling to accept and meet study requirements. Use of an investigational drug or participation in an investigational study within 30 days prior to application of study medication. Alcohol or substance abuse. AIDS symptoms or any other immunodeficiency. Additional exclusion criteria for females only: Breast-feeding patients. Positive urine pregnancy test at screening (performed for all females of child bearing potential or for those in non- surgical post-menopause for less than 1 year). Female of childbearing potential having unprotected sexual intercourse with any non-sterile male partner (i.e., a male who has not been sterilized by vasectomy at least 6 months prior to drug application) within 14 days prior to study drug application. Acceptable methods of contraception are the following: condom, diaphragm, intrauterine contraceptive device (placed at least 4 weeks prior to study drug application), pill + condom. Eligible patients will be randomized to either [STUDY DRUG] or vehicle, in a 1:1 ratio according to a computer-generated randomization list. Randomization will be performed using permuted blocks. The randomization process will be managed centrally through the e-crf. All patients shall apply the allocated treatment once daily, preferably at bedtime, on clean and dry nail(s). The solution dries in approximately 30 seconds. A single layer of the product will be applied over the entire nail plate and 5 mm of surrounding skin. If possible, it will be applied to the nail bed, nail matrix and under the free edge of the nail. The nails shall not be washed for at least six hours after application, therefore, it will be recommended to preferably apply the product at bedtime. To remove the product it is sufficient to wash the nails. No solvent is needed. Eight visits are scheduled for each patient. The following are expected: screening: Visit 0 randomization: Visit 1 treatment: Visits 2, 3, 4, 5 and 6 (four weeks between visit 1
8 Not Allowed Medication Sample Size Analysis Populations and 2, eight weeks between Visits 2 and 3, the other visits during treatment are every four weeks) follow-up: Visit 7 (4 weeks after the end of treatment) Any systemic treatment for psoriasis and/or nail psoriasis (topical treatments on skin are allowed). Any topical product on fingernails (cosmetic or topical treatment for nail psoriasis). Photochemotheraphy (phototherapy is allowed) or other forms of radiotherapy. Systemic immunosuppressives, chemotherapy, corticosteroids. Oral Vitamin D or its analogues for any reason. At least 470 patients should be randomized, 235 patients in each treatment group. A total sample size of 390 evaluated patients (195 patients per treatment arm) will provide a power of at least 90% to detect a difference of 12% in the percentage of patients with Target nail NAPSI = 0 at the endpoint visit (24 weeks), 10% vehicle arm versus 22% in active treatment arm. A 0.05 two-sided significance level was set (nquery Advisor, two-sided Chi-Square Test). The primary analyses of efficacy will be based on a Full Analysis Set (FAS) consisting of all randomized patients to whom investigational drug is dispensed. Following the intent-to-treat principle, patients in the FAS population will be analyzed according to the treatment to which they were randomized. A Per Protocol (PP) population will consist of all patients in the FAS population who complete the study fully compliant with the protocol and without any major deviation likely to affect the nail bed or nail matrix assessments. Patients in the PP population will be analyzed according to the treatment they actually received. Efficacy analyses based on PP population will be performed in order to confirm the robustness of the results. The Safety population will consist of all randomized patients with at least one documented application of any study drug. It will be the basis for the analyses of safety. Patients in the Safety population will be analyzed according to the treatment they actually received. Of note, a statement that a patient experienced no adverse events also constitutes a safety assessment.
9 Statistical Methods All efficacy analyses will be performed on the FAS population. Also, analysis of the primary and secondary efficacy variables will be carried out on the Per Protocol population to assess the robustness of the findings. Safety outcomes will be analysed on the Safety population. The primary efficacy endpoint Proportion of patients with clear target nail (NAPSI = 0) at Week 24 will be analysed on the FAS population by means of a generalized linear model parameterized with logit link function, binomial distribution and with treatment and center as factors. Hypothesis testing of active treatment versus placebo and two-sided 95% confidence intervals for the odds ratios will be calculated based on previous described model, using the Wald statistic. Same approach will be used for Proportion of patients with clear target nail bed (bed NAPSI =0) at Week 24, Proportion of patients with clear target nail matrix (matrix NAPSI =0) at Week 24 and Proportion of patients with target nail reaching NAPSI- 75% at Week 24. The Proportion of affected nails at baseline with NAPSI = 0 at Week 24 and the Proportion of affected nails at baseline reaching NAPSI-75% at Week 24 will be analysed by a generalized linear mixed effects model for repeated measures with the identity link function and binomial distribution for the proportion of affected nails that become completely cleared of psoriatic signs will be estimated with treatment group, center, visit and treatment-by-visit interaction as fixed effects and with an unstructured variance-covariance matrix to take into account correlations among repeated measures within patient. A maximum likelihood estimate of the treatment difference in the proportions at Week 24 will be reported together with its associated two-tailed 95% CI. For the changes from baseline in continuous variables, a linear mixed effects model for repeated measures will be estimated with treatment group, center, visit and treatment-by-visit interaction as fixed effects, baseline value as covariate, and with an unstructured variance-covariance matrix to take into account correlations among repeated measures within patient. A maximum likelihood estimate of the difference between the least squares treatment means at Week 24 will be reported together with its associated two-tailed 95% CI. Missing data on the primary endpoint ( Proportion of patients with clear target nail (NAPSI=0) at Week 24 ) will be imputed as treatment failures (MVTF) as the primary imputation method and
10 using multiple imputation (MI) and last observation carried forward (LOCF) as sensitivity analyses. Stratified Wilcoxon Rank Sum test blocking for center will compare the treatments with respect to Patient acceptance of study therapy at Week 24. The overall type I family-wise error rate for testing the primary and the secondary efficacy parameters will be controlled at the 0.05 significance level using a 3-step serial gatekeeping multiple comparisons procedure (MCP). This procedure will be fully described in the protocol.
Supplementary Online Content
Supplementary Online Content Foley P, Gordon K, Griffiths, CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized
More informationPatients who achieved the primary criterion for response i.e.: complete clearance or a reduction
MC 9101 F Study Page3 ABSTRACT Background: Cyclosporin A has been shown to be an effective systemic treatment in severe psoriasis but with the disadvantage of dose-dependent toxic effects particularly
More informationAdalimumab M Clinical Study Report Final R&D/16/0603
Methodology (Continued): The 70-day safety follow-up period started from the last dose of study drug, but was not required for any subject who initiated commercial Humira after study completion. Additional
More information2 SYNOPSIS. Study code : MC 9308 FR.
MC9308 FR Study 19 December 2000 Page 15 of142 2 SYNOPSIS Study code : MC 9308 FR. Title: A comparative study of calcipotriol ointment in combination with narrow-band UVB (TL-01) phototherapy and placebo
More informationPFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A3924 4 November 24 Final PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. GENERIC DRUG NAME / COMPOUND NUMBER: Tofacitinib / CP-690,550
More informationSynopsis. Adalimumab M Clinical Study Report R&D/09/060. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Volume: (For National Authority Use Only) Name of Active Ingredient: Page: Title of Study: A Multi-Center,
More informationClinical Trial Report Synopsis
This document has been do\vnloaded from \v ww.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationClinical Trial Report Synopsis
Clinical Trial Report Synopsis A phase 2a, proof of concept trial, testing twice daily application of LEO 124249 ointment 30 mg/g in the treatment of mild to moderate inverse psoriasis Design of trial:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationSupplementary materials
Supplementary materials Table S Adverse events identified by participants diary logs and blood hematologic and biochemical tests (n=2) group (n=) Placebo group (n=) P value for chi-squared test Asthma
More informationIndividual Study Table Referring to Part of the Dossier. Use only) Name of Finished Product:
SYNOPSIS Fresenius Title of the study: A double-blind, randomized study comparing the safety and torelance of SMOFlipid 20% and Intralipid 20% in long-term treatment with parenteral nutrition Coordinating
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More information11 August 2000 Page 17 of 181. Subtitle A prospective, multicentre, randomised, double-blind, vehicle-controlled, parallel groupr comparative study.
Study MCO 9604 DE 11 August 2000 Page 17 of 181 2 SYNOPSIS Study Code MCO 9604 DE. Title Addition of Daivonex (calcipotriol) ointment (50 J.Lg!g) to fumaric acid therapy in patients with severe psoriasis
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationSynopsis (C0743T09 PHOENIX 2)
Monoclonal antibody () Synopsis ( PHOENIX 2) Protocol: EudraCT No.: 2005-003530-17 Title of the study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More information2 Synopsis. Name of Sponsor/Company: Volume: Page: (For National Authority Use Only) Almirall Hermal GmbH. Name of Finished Product: LAS 41004
2 Synopsis Title of study: An Investigator-blind, Controlled Exploratory Study to Assess the Efficacy and Safety of Different Concentrations of Active Ingredients in the project Formulations of Compared
More informationResearch Data Available
Research Data Available Main Questionnaire General Topic Socio-economic status Occupational exposure Physical activity Mobile phone usage Sleeping patterns smoking Childhood conditions/illnesses/family
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More informationPage: 17 December 2012 (Study M13-692) 22 October 2013 (Study M13-692)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: D2E7 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Studies:
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationMipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3
(ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,
More informationClinical Trial Report Synopsis. Patient insights following use of LEO aerosol foam and Daivobet gel in subjects with psoriasis vulgaris
This document has been downloaded from W\vw.leo-pharma.com subject to the ten:n.s of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationGuselkumab (plaque psoriasis)
IQWiG Reports Commission No. A18-24 Guselkumab (plaque psoriasis) Addendum to Commission A17-60 1 Addendum Commission: A18-24 Version: 1.0 Status: 27 April 2018 1 Translation of addendum A18-24 Guselkumab
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationGSK , 2.0, 18, 2014, DAIDS
Letter of Amendment # 1 to: HPTN 077: A Phase IIa Study to Evaluate the, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationAdalimumab M Clinical Study Report Final R&D/14/1263. Page:
Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:
More informationWhat is PlaqueOff (PO)? A new study in Beagle dogs. Oral effects of
Oral effects of What is? PO is a dry food supplement. Sprinkle it onto your pet s food daily. PO is an algae that has been harvested in the Atlantic ocean in northern Norway and contains nothing else such
More informationSponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title
Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationInstructions concerning lifestyle and concomitant medications
Appendix S1. Supporting information STUDY 1: Double-blind, vehicle-controlled, single centre, two-period, Phase I study to investigate pharmacokinetics, safety and tolerability of a single topical dose
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPlattenepithelkarzinom des Ösophagus, 1 st -line
Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced
More informationClassification. Distal & Lateral Subungual OM. White Superficial OM. Proximal Subungual OM. Candidal OM. Total dystrophic OM
Onychomycosis Commonest dermatological condition Definition: Infection of the nail caused by fungi that include dermatophytes, non-dermatophyte moulds and yeasts (mainly Candida). 80% of all OM affects
More informationSynopsis. Study Phase and Title: Study Objectives: Overall Study Design
Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib
More informationStatistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study
1.0 Page 1 of 15 FINAL DexComG4 (DexCom Corporation) CGMMDI GOLD-Study monitoring (CGM) in individuals with type 1 diabetes treated 2016-07-07 Approvals Name/Title: Nils-Gunnar Pehrsson / Statistiska Konsultgruppen,
More information24-Week CNTO1275PSA3001 Clinical Study Report
24-Week CNTO1275PSA3001 Clinical Study Report SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, Inc Ustekinumab
More informationAquila Smoldering Multiple Myeloma
Inklusionskriterier: Ja Nej 1. At least 18 years of age or at least the legal age of consent in the jurisdiction in which the study is taking place, whichever is the older age. 2. Diagnosis of SMM for
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationSubject ID: I N D # # U A * Consent Date: Day Month Year
IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be
More informationSynopsis. Study title. Investigational Product Indication Design of clinical trial. Number of trial sites Duration of clinical trial / Timetable
Synopsis Study title Investigational Product Indication Design of clinical trial Number of trial sites Duration of clinical trial / Timetable Repetitive levosimendan infusions for patients with advanced
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More information1.2. Protocol number 6078-PG-PSC EU trial number
1. Clinical trial identification Researchers look at the results of many studies to decide which drugs work best and are safest for patients. It takes participants in many studies all around the world
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More informationFullerton Healthcare Screening Centres
Fullerton Healthcare Screening Centres Fullerton Healthcare Screening Centre @ Ngee Ann City The Penthouse, #26-02 Ngee Ann City Tower B, 391B Orchard Road, Singapore 238874 Operating hours: Monday - Friday
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
2 Synopsis Title of study: An Investigator-blind, Controlled Study to Assess the Efficacy and Safety of Different Formulations of Compared to Placebo and to Active Control in a Psoriasis Plaque Test Investigators
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationElements of Successful PBS Applications. Barbara Radulski RN. Copyright
Elements of Successful PBS Applications Barbara Radulski RN PBS Requirements April 1 2006 THE RULES PBS Requirements 18 years and over Psoriasis x 6 months Failed to achieve an adequate response to 3 systemic
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Chen CL, Lin GA, Bardach NS, et al. Preoperative medical testing
More informationCycle 1-6 (28 Days) Days 15&16 1&2 8. (±2 Days) (±2 Days) (±7 Days) (+7 days) X X X X X X X
Table 5 Schedule of Assessments A Cycles A-D and Cycles 1-6 (AZD4573 Monotherapy) Assessment Screen a Intra-subject Dose Escalation/ramp -up (Cycles a-d Cycle=14 days) z Days 1, 2, 15 & 16 Visits 1&2 8
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
2 Synopsis Title of study: An Investigator-blind, Controlled Study to Assess the Efficacy of Five Distinct Combinations of in Different Concentrations Compared to Placebo and to Two Active Controls in
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Niaspan Name of Active Ingredient: Page: Niacin extended-release
More informationH.6.G.2 Non-MAC Studies
Page 63 H.6.G.2 Non-MAC Studies H.6.G.2.A Non-MAC Studies at the 600 mg dose A 600 mg dose of azithromycin was given in two non-mac studies (354/354A and 167). Please note: Study 354/354A enrolled a mixture
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationThe Nail Psoriasis Severity Index (NAPSI): Validation of an Instrument to Assess Psoriatic Nail Involvement
The Nail Psoriasis Severity Index (NAPSI): Validation of an Instrument to Assess Psoriatic Nail Involvement Julie Jefferson 1, Racheal Manhart 2, Jill Moore 3 Richard Scher 4, Phoebe Rich 5 1Dermatology,
More informationIxekizumab (plaque psoriasis)
IQWiG Reports Commission No. A17-07 Ixekizumab (plaque psoriasis) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ixekizumab
More informationReferring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University
More informationAbstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Abstract and Schema Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary CNS
More informationOTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone Patients with moderate to severe plaque psoriasis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one
SYNOPSIS Issue Date: 18 November 2008 Document No.: EDMS-PSDB-9006510:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Ortho-McNeil Janssen Scientific Affairs, L.L.C. Paliperidone
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationProtocol Number: BV-2005/01. OM Pharma OM-85
Page 3 SYNOPSIS Protocol Number: Name of Finished Product: Broncho-Vaxom (Broncho-Munal ) Title: Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom in Children Suffering from
More informationPatients must have met all of the following inclusion criteria to be eligible for participation in this study.
Supplementary Appendix S1: Detailed inclusion/exclusion criteria Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Inclusion Criteria 1) Willing
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial
More informationFigure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time.
Figure 1: PALLAS Study Schema Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Approximately 4600 patients from approximately 500 global sites will be randomized
More informationEtanercept for Treatment of Hidradenitis
Home Search Browse Resources Help What's New About Purpose Etanercept for Treatment of Hidradenitis This study is currently recruiting patients. Sponsors and Collaborators: University of Pennsylvania Amgen
More informationSummary ID# Clinical Study Summary: Study F1J-MC-HMDV
CT Registry ID# 7108 Page 1 Summary ID# 7108 Clinical Study Summary: Study F1J-MC-HMDV Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
More information